Development of two different eco-friendly label-free platforms for analysis of selumetinib

1 D. H. Gutmann, R. E. Ferner, R. H. Listernick, B. R. Korf, P. L. Wolters and K. J. Johnson, Neurofibromatosis type 1, Nat. Rev. Dis. Primer 3 (2017) Article ID 17004; https://doi.org/10.1038/nrdp.2017.4 Search in Google Scholar

2 A. S. Michaels, Neurofibromatosis: Causes, Tests and Treatment Options (2nd ed.), CreateSpace Independent Publishing Platform, Scotts Valley (CA, USA) 2014. Search in Google Scholar

3 I. Solares, D. Viñal, M. Morales-Conejo, N. Rodriguez-Salas and J. Feliu, Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: A comprehensive review, ESMO Open 6(4) (2021) Article ID 100223 (10 pages); https://doi.org/10.1016/j.esmoop.2021.100223 Search in Google Scholar

4 R. Roskoski, Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update, Pharmacol. Res. 165 (2021) Article ID 105463; https://doi.org/10.1016/j.phrs.2021.105463 Search in Google Scholar

5 D. Casey, S. Demko, A. Sinha, P. S. Mishra-Kalyani, Y.-li Shen, S. Khasar, M. A. Goheer, W. S. Helms, L. Pan, Y. Xu, J. Fan, R. Leong, J. Liu, Y. Yang, K. Windsor, M. Ou, O. Stephens, B. Oh, G. H. Reaman, A. Nair, S. S. Shord, V. Bhatnagar, S. R. Daniels, S. Sickafuse, K. B. Goldberg, M. R. Theoret, R. Pazdur and H. Sing, FDA approval summary: Selumetinib for plexiform neurofibroma, Clin. Cancer Res. 27(15) (2021) 4142–4146; https://doi.org/10.1158/1078-0432.CCR-20-5032 Search in Google Scholar

6 U.S. Food & Drug Administration, FDA Approves Selumetinib for Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas, US-FDA, Silver Spring (MD, USA), April 13, 2020; https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selumetinib-neurofibromatosis-type-1-symptomatic-inoperable-plexiform-neurofibromas; last access date September 22, 2024. Search in Google Scholar

7 S. V. Holt, A. Logié, R. Odedra, A. Heier, S. P. Heaton, D. Alferez, B. R. Davies, R. W. Wilkinson and P. D. Smith, The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models, Br. J. Cancer 106 (2012) 858–866; https://doi.org/10.1038/bjc.2012.8 Search in Google Scholar

8 C. Li, Z. Chen, H. Yang, F. Luo, L. Chen, H. Cai, Y. Li, G. You, D. Long, S. Li, Q. Zhang and L. Rao, Selumetinib, an oral anti-neoplastic drug, may attenuate cardiac hypertrophy via targeting the ERK pathway, PloS One 11 (2016) e-0159079; https://doi.org/10.1371/journal.pone.0159079 Search in Google Scholar

9 FDA – Center for Drug Evaluation and Research, NDA Multi-disciplinary Review and Evaluation NDA 213756 Koselugo (selumetinib), Version July 24, 2019, US FDA-CDER, Silver Spring (MD, USA), February 2020; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213756Orig1s000MultidisciplineR.pdf; last access date August 3, 2024. Search in Google Scholar

10 K. K. Saindane, H. Talapadatur, V. K. Munipalli, R. M. Singh, B. Fegade and V. Bhaskar, Stability indicating RP-HPLC method for the estimation of selumetinib in capsule dosage form, Int. J. Pharm. Sci. Rev. Res. 74 (2022) 166–174; https://doi.org/10.47583/ijpsrr.2022.v74i02.026 Search in Google Scholar

11 P. Severin, C. Bailey, M. Chen, A. Fisher and V. Holmes, Determination of selumetinib, N-desmethyl selumetinib and selumetinib amide in human biological samples by LC-MS/MS, Bioanalysis 8 (2016) 1919–1936; https://doi.org/10.4155/bio-2016-0082 Search in Google Scholar

12 J. Li, Z. Zhang, M. Yan, S. Yang, Y. Song and J. Dong, Determination of selumetinib in rat plasma by UPLC-MS/MS and application to a pharmacokinetic study, Lat. Am. J. Pharm. 39 (2020) 237–342. Search in Google Scholar

13 R. R. Voggu, T. S. Brus, C. T. Barksdale, P. Severin, P. Hansen, R. Chudnovskiy, E. Thomas and C. Bailey, Novel LC-MS/MS method for the determination of selumetinib (AZD6244) in whole blood collected with volumetric absorptive microsampling, Bioanalysis 12 (2020) 883–892; https://doi.org/10.4155/bio-2020-0062 Search in Google Scholar

14 S. Alrubia, W. A. AlShehri, A. A. Radwan, N. Z. Alzoman and I. A. Darwish, Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro--5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation, BMC Chemistry 19 (2025) Article ID 27 (17 pages); https://doi.org/10.1186/s13065-024-01353-6 Search in Google Scholar

15 I. A. Darwish and N. Z. Alzoman, Development of green and high throughput microplate readerassisted universal microwell spectrophotometric assay for direct determination of tyrosine kinase inhibitors in their pharmaceutical formulations irrespective the diversity of their chemical structures, Molecules 28(10) (2023) Article ID 4049 (19 pages); https://doi.org/10.3390/molecules28104049 Search in Google Scholar

16 International Conference for Harmonisation (ICH), Harmonised Guideline Q2 (R1) Validation of Analytical Procedures: Text and Methodology, Geneva, Dec 2023; Retrieved from https://database.ich.org/sites/default/files/ICH_Q2-R2_Document_Step2_Guideline_2022_0324.pdf; last access date March 18, 2025. Search in Google Scholar

17 International Conference for Harmonisation (ICH)/EMA, Harmonised Guideline (M10) Bioanalytical Method Validation and Study Sample Analysis-Step 4, Geneva, May 2022; https://database.ich.org/sites/default/files/M10_Guideline_Step4_2022_0524.pdf; last access date March 18, 2025. Search in Google Scholar

18 Waters, Wavelength cutoffs for common solvents; https://help.waters.com/help/en/product-support/alliance-is-system-support/715008450/6BCFA49.html; last access date March 18, 2025. Search in Google Scholar

19 A. Yusaf, M. Usman, A. Mansha, M. Siddiq, Z. Amjad, S. Irshad and H. Sultana, Self-organised surfactant assemblies as nanostructured dye carriers: a mixed micellar comparative approach for enhanced dye solubilisation, Int. J. Environ. Anal. Chem. 104 (2024) 2352–2363; https://doi.org/10.1080/03067319.2022.2060747 Search in Google Scholar

20 A. A. Rana, A. Yusaf, S. Shahid, M. Usman, M. Ahmad, S. Aslam, S. A. Al-Hussain and M. E. A. Zaki, Unveiling the role of nonionic surfactants in enhancing cefotaxime drug solubility: A UVvisible spectroscopic investigation in single and mixed micellar formulations, Pharmaceuticals 16(12) (2023) Article ID 1663; https://doi.org/10.3390/ph16121663 Search in Google Scholar

21 P. Patel, E. Howgate, P. Martin, D. J. Carlile, L. Aarons and D. Zhou, Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials, Br. J. Clin. Pharmacol. 84 (2018) 52–63; https://doi.org/10.1111/bcp.13404 Search in Google Scholar

22 F. Shakeel, S. Alshehri, M. A. Ibrahim, M. Altamimi, N. Haq, E. M. Elzayat and G. A. Shazly, Solubilization and thermodynamic properties of simvastatin in various micellar solutions of different non-ionic surfactants: Computational modeling and solubilization capacity, PLoS ONE 16 (2021) e0249485; https://doi.org/10.1371/journal.pone.0249485 Search in Google Scholar

23 ChemAxon. MarvinSketch Version 23.12., (Chemaxon Ltd., Budapest, Hungary); Retrieved from https://chemaxon.com/marvin; last access date March 18, 2025. Search in Google Scholar

24 D. Malyshev, R. Öberg, L. Landström, P. O. Andersson, T. Dahlberg and M. Andersson, pH-induced changes in Raman, UV-Vis absorbance, and fluorescence spectra of dipicolinic acid (DPA), Spectrochim. Acta A 271 (2022) Article ID 120869 (8 pages); https://doi.org/10.1016/j.saa.2022.120869 Search in Google Scholar

25 S. Armenta, S. Garrigues and M. de la Guardia, Green analytical chemistry, TrAC Trends Anal. Chem. 27 (2008) 497–511; https://doi.org/10.1016/j.trac.2008.05.003 Search in Google Scholar

26 A. Gałuszka, Z. M. Migaszewski, P. Konieczka and J. Namieśnik, Analytical Eco-Scale for assessing the greenness of analytical procedures, TrAC Trends Anal. Chem. 37 (2012) 61–72; https://doi.org/10.1016/j.trac.2012.03.013 Search in Google Scholar

27 J. Płotka-Wasylka, A new tool for the evaluation of the analytical procedure: Green analytical procedure index, Talanta 181 (2018) 204–209; https://doi.org/10.1016/j.talanta.2018.01.013 Search in Google Scholar

28 F. Pena-Pereira, W. Wojnowski and M. Tobiszewski, AGREE – Analytical GREEnness Metric approach and software, Anal. Chem. 92 (2020) 10076–10082; https://doi.org/10.1021/acs.analchem.0c01887 Search in Google Scholar